At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 45 enrolled
Drug / intervention
Quillivant Oral Suspension XR +2 moredrug
Likely dose
Quillivant Oral Suspension XR 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study
In Brief
A Phase 3 clinical trial evaluating Quillivant Oral Suspension XR and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 45 participants across 2 sites.
Detailed Summary
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages 6-12 years with ADHD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedMay 2009
Primary CompletionAug 2009
TodayJul 2026
First PostedMay 20, 2009
Enrollment StartApr 1, 2009
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.1 years ago
Interventions
Quillivant Oral Suspension XRdrug
Oral Suspension 25mg/5mL; 20-60 mg/day
Placebodrug
Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
Placebodrug
Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.